Influenza virus-like particles as a new tool for vaccine immunogenicity testing: Validation of a neuraminidase neutralizing antibody assay

Journal of Virological Methods

Volumn 173, Issue 2, 2011, Pages 364-373

  Gavrilov, Victor ^a   Orekov, Tatyana ^a   Alabanza, Casper ^a   Porika, Udayasree ^a   Jiang, Hua ^a   Connolly, Kevin ^a,b   Pincus, Steven ^a  

^a NOVAVAX INC   (United States)

^b PharmAthene Inc   (United States)

Author keywords

Assay validation; Influenza virus like particle; Neuraminidase neutralizing antibody; Vaccine immunogenicity

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; PROTEIN M1; UNCLASSIFIED DRUG; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; VIRUS SIALIDASE;

ADULT; ANIMAL EXPERIMENT; ANTIBODY DETECTION; ANTIBODY TITER; ARTICLE; BACULOVIRUS; CONTROLLED STUDY; ENZYME ACTIVITY; FERRET; HUMAN; HUMAN EXPERIMENT; IMMUNITY; IMMUNIZATION; IMMUNOASSAY; IMMUNOGENICITY; INFLUENZA VIRUS LIKE PARTICLE; INSECT CELL; NONHUMAN; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIRUS LIKE AGENT; VIRUS STRAIN;

ADOLESCENT; ADULT; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; FEMALE; FERRETS; HUMANS; INFLUENZA VACCINES; MALE; MIDDLE AGED; NEURAMINIDASE; NEUTRALIZATION TESTS; ORTHOMYXOVIRIDAE; REPRODUCIBILITY OF RESULTS; VIROLOGY; VIROSOMES; YOUNG ADULT;

HEXAPODA; ORTHOMYXOVIRIDAE;

EID: 79954594723     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2011.03.011     Document Type: Article

References (21)

1. Bosch B.J., Bodewes R., de Vries R.P., Kreijtz J.H., Bartelink W., van Amerongen G., Rimmelzwaan G.F., de Haan C.A., Osterhaus A.D., Rottier P.J. Recombinant soluble, multimeric HA and NA exhibit distinctive types of protection against pandemic swine-origin 2009 A(H1N1) influenza virus infection in ferrets. J. Virol. 2010, 84:10366-10374.
2. Bright R.A., Carter M., Crevar C.J., Toapanta F.R., Steckbeck J.D., Cole K.S., Kumar N.J., Pushko P., Smith G., Tumpey T.M., Ross T.M. Cross-clade protective immune responses to influenza viruses with H5N1 HA and NA elicited by an influenza virus-like particle. PLoS One 2008, 1:e1501.
3. Bright R.A., Carter D.M., Daniluk S., Toapanta F.R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T.M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007, 25:3871-3878.
4. Cate T.R., Rayford Y., Nino D., Winokur P., Brady R., Belshe R., Chen W., Atmar R.L., Couch R.B. A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 2010, 28:2076-2079.
5. Chaloupka I., Schuler A., Marschall M., Meier-Ewert H. Eur. J. Clin. Microbiol. Infect. Dis. 1996, 15:121-127.
6. Feng J., Gulati U., Zhang X., Keitel W.A., Thompson D.M., James J.A., Thompson L.F., Air G.M. Antibody quantity versus quality after influenza vaccination. Vaccine 2009, 27:6358-6362.
7. Gubareva L.V., Webster R.G., Hayden F.G. Detection of influenza virus resistance to neuraminidase inhibitors by an enzyme inhibition assay. Antiviral Res. 2002, 53:47-61.
8. Hassantoufighi A., Zhang H., Sandbulte M., Gao J., Manishewitz J., King L., Golding H., Straight T.M., Eichelberger M.C. A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 2010, 28:790-797.
9. International Conference on Harmonization (ICH) of Technical Requirements for the Registration of Pharmaceuticals for Human Use, Validation of Analytical Procedures: Methodology, adopted in 1996, Geneva.
10. Johansson B.E., Bucher D.J., Kilbourne E.D. Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J. Virol. 1989, 63:1239-1246.
11. Kalbfuss B., Knochlein A., Krober T., Reichl U. Monitoring influenza virus content in vaccine production: precise assays for the quantitation of hemagglutination and neuraminidase activity. Biologicals 2008, 36:145-161.
12. Kang S., Song J., Quan F., Compans R.W. Influenza vaccines based on virus-like particles. Viral Res. 2009, 143:140-146.
13. Kendal A.P., Bozeman F.M., Ennis F.A. Further studies of the neuraminidase content of inactivated influenza vaccines and the neuraminidase antibody responses after vaccination of immunologically primed and unprimed populations. Infect. Immun. 1980, 29:966-971.
14. Lai J.C.C., Chan W.W.L., Kien F., Nicholls J.M., Malik Peiris J.S., Garcia J.M. Formation of virus-like particles from human cell lines exclusively expressing influenza neuraminidase. J. Gen. Virol. 2010, 91:2322-2330.
15. Lambre C.R., Chauvaux S., Pilatte Y. Fluorometric assay for the measurement of viral neuraminidase in influenza vaccines. Vaccine 1989, 7:104-105.
16. Mahmood K., Bright R.A., Mytle N., Carter D.M., Crevar C.J., Achenbach J.E., Heaton P.M., Tumpey T.M., Ross T.M. H5N1 VLP vaccine induced protection in ferrets against lethal challenge with highly pathogenic H5N1 influenza viruses. Vaccine 2008, 26:5393-5399.
17. Potier M., Mameli L., Belisle M., Dallaire L., Melancon S.B. Flurometric assay of neuraminidase with a sodium (4-methylumbelliferyl-α-d-N-acetylneuraminate) substrate. Anal. Biochem. 1979, 94:287-296.
18. Pushko P., Tumpey T.M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005, 23:5751-5759.
19. Sylte M.J., Suarez D.L. Influenza neuraminidase as a vaccine antigen. Vaccines for Pandemic Influenza, Current Topics in Microbiology and Immunology 333 2010, 227-241. Springer-Verlag, Berlin Heidelberg. R.W. Compans, W.A. Orenstein (Eds.).
20. Sylte M.J., Hubby B., Suarez D.L. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007, 25:3763-3772.
21. Wetherall N.T., Trivedi T., Zeller J., Hodges-Savola C., McKimm-Breshkin J.L., Zambon M., Hayden F.G. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J. Clin. Microbiol. 2003, 41:742-750.